In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Reata nets $492mm through public offering

Executive Summary

Reata Pharmaceuticals Inc. netted $492mm through a public offering of 2.76mm Class A common shares (including the overallotment) at $183. Proceeds will support continued development and future commercialization of lead candidates bardoxolone (Phase III for chronic kidney disease caused by Alport syndrome) and omaveloxolone (Phase II for Friedreich's ataxia). Money will also be used to make payments due to AbbVie following Reata's reacquisition of all rights to bardoxolone and omaveloxolone earlier this year. (AbbVie had global rights (excluding US and Asia) to the candidate under a 2010 deal, which Reata terminated in October. It now owes AbbVie $330mm, primarily for the rights to bardoxolone.)
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

UsernamePublicRestriction

Register